• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Apyx Medical Corporation Announces Board Leadership Transition

    5/9/24 7:00:00 AM ET
    $APYX
    $BVS
    $XTNT
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $APYX alert in real time by email

    Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors;

    Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman

    Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024.

    "On behalf of the entire organization, I would like to express our gratitude to Andrew for his leadership and the immense contributions made during his more than 40-year tenure at Apyx Medical," said Charlie Goodwin, President and Chief Executive Officer. "Andrew has served continuously as Chairman of the Board since co-founding Apyx Medical in 1982, while also leading the Company in multiple senior leadership roles, including as its President from 1985 until 2011 and Chief Executive Officer from 1998 until 2013. His dedication, vision and thoughtful guidance have been instrumental to the development of our organization from a start-up to a leading, Nasdaq-listed, advanced energy company serving customers in more than 60 countries. We wish him the best in his future endeavors as he begins retirement."

    Mr. Goodwin continued: "I am also pleased to welcome Stavros to the Chairman role, who joins our Board of Directors following an impressive career in the medical device industry, including significant leadership experience as both a director and senior executive of publicly-traded medical device companies. I look forward to working together as we pursue the next stage of growth for Apyx Medical."

    "It has been one of the greatest privileges of my life to serve Apyx Medical and its stakeholders, while working alongside so many talented individuals during my tenure," said Andrew Makrides. "Thank you to my fellow board members, and everyone who I have worked with, for your support. I look forward to the Company's future success under new leadership and believe it is well-positioned to build upon the many achievements we have made in recent years."

    "I am honored to be named Chairman of the Board during this important time in the Company's evolution as a leading provider of advanced energy technologies," said Stavros Vizirgianakis. "I believe our Helium Plasma Technology has the potential to revolutionize the cosmetic surgery market and look forward to partnering with fellow directors and colleagues as we drive strong growth and value creation for the benefit of all Apyx Medical stakeholders."

    Additional details regarding the foregoing are set forth in the Company's Current Report on Form 8-K filed with the SEC on May 9, 2024.

    About Stavros Vizirgianakis

    Stavros Vizirgianakis is an investor and strategic advisor to companies in the medical device field. He currently serves on the Board of Directors at the following healthcare companies: Tally Surgical, Inc.; Theragenics Corporation; Xtant Medical Holdings, Inc. (NYSE:XTNT); and Medinotec, Inc. (OTCQX:MDNC). Mr. Vizirgianakis previously served on the Board of Directors at Bioventus Inc. (NASDAQ:BVS) and Tenaxis Medical.

    Mr. Vizirgianakis is the former Chief Executive Officer of medical device company, Misonix, Inc., which he led from 2016 through the company's acquisition by Bioventus Inc. in 2021. He previously served as Managing Director of the Medical Devices business at Ascendis Health Limited (JSE: ASC) from 2014 to 2016. Mr. Vizirgianakis co-founded Surgical Innovations, one of the largest privately-owned medical device distributors in the African region, which later became part of Ascendis Health Limited. His career in the medical device industry also includes experience serving as Director of Sales for sub-Saharan Africa at United States Surgical Corporation and as General Manager of South Africa at Tyco Healthcare. Mr. Vizirgianakis holds a degree in Commerce from the University of South Africa.

    About Apyx Medical Corporation:

    Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website www.ApyxMedical.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240509838744/en/

    Get the next $APYX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APYX
    $BVS
    $XTNT

    CompanyDatePrice TargetRatingAnalyst
    Bioventus Inc.
    $BVS
    7/7/2025$12.00Overweight
    Cantor Fitzgerald
    Bioventus Inc.
    $BVS
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    Apyx Medical Corporation
    $APYX
    10/17/2024Neutral
    BTIG Research
    Bioventus Inc.
    $BVS
    12/7/2023$7.00Hold → Buy
    Canaccord Genuity
    Xtant Medical Holdings Inc.
    $XTNT
    12/5/2023$2.00Buy
    BTIG Research
    Bioventus Inc.
    $BVS
    8/9/2023$4.00 → $6.00Hold → Buy
    Craig Hallum
    Apyx Medical Corporation
    $APYX
    7/14/2023$8.00Overweight
    Stephens
    Bioventus Inc.
    $BVS
    11/22/2022Buy → Hold
    Craig Hallum
    More analyst ratings

    $APYX
    $BVS
    $XTNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

      CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the second quarter of fiscal year 2025 will be released after markets closes on Thursday, August 7th. Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 7th, to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international c

      7/24/25 4:05:00 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Companion Spine LLC Announces Definitive Agreement to Acquire the Business and Assets of Paradigm Spine GmbH and the Coflex® and CoFix® Spine Implants from Xtant™ Medical Holdings, Inc.

      Strategic step to strengthen Companion Spine's global leadership in posterior dynamic spine stabilization and spine motion preservation. The combined product portfolio will reinforce Companion Spine's innovative and leading international business platform focused on the treatment of spine pain resulting from lumbar spinal stenosis and degenerative disc disease, two of the main causes of disability globally. Anticipated completion of the acquisition is in 3Q25. Companion Spine LLC ("Companion Spine" or "the Company"), the French-American specialist in spine pain-management surgery, announced that it has entered into a definitive agreement to acquire the Coflex® Interlaminar Stabi

      7/8/25 9:01:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine

      Transaction expected to facilitate enhanced focus on Xtant's core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, Mont., July 8, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilizatio

      7/8/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APYX
    $BVS
    $XTNT
    SEC Filings

    See more
    • Xtant Medical Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

      7/8/25 8:10:27 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Apyx Medical Corporation

      DEF 14A - Apyx Medical Corp (0000719135) (Filer)

      6/25/25 9:10:45 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by Apyx Medical Corporation

      PRE 14A - Apyx Medical Corp (0000719135) (Filer)

      6/13/25 4:10:59 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    $BVS
    $XTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bartholdson John A. converted options into 7,575 shares, increasing direct ownership by 11% to 79,620 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/10/25 5:49:16 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Director Bartholdson John A. converted options into 26,493 shares, increasing direct ownership by 58% to 72,045 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/5/25 9:22:27 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Director Sutter Martin P converted options into 26,493 shares, increasing direct ownership by 45% to 85,241 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/4/25 9:30:50 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $APYX
    $BVS
    $XTNT
    Financials

    Live finance-specific insights

    See more
    • Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

      CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the second quarter of fiscal year 2025 will be released after markets closes on Thursday, August 7th. Management will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 7th, to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international c

      7/24/25 4:05:00 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine

      Transaction expected to facilitate enhanced focus on Xtant's core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, Mont., July 8, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilizatio

      7/8/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Reports First Quarter 2025 Financial Results

      Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont., May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $32.9 million, up 18%, compared to the prior year quarterGross margin of 61.5% compared to 62.1% for the prior year quarterNet income of $58,000 compared to a net lo

      5/12/25 4:05:00 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APYX
    $BVS
    $XTNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

      4/A - Apyx Medical Corp (0000719135) (Issuer)

      3/3/25 4:05:12 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      8/20/24 6:16:00 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Hill Matthew C bought $6,030 worth of shares (5,336 units at $1.13), increasing direct ownership by 213% to 7,836 units (SEC Form 4)

      4 - Apyx Medical Corp (0000719135) (Issuer)

      8/13/24 6:56:00 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    $BVS
    $XTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Bioventus with a new price target

      Cantor Fitzgerald initiated coverage of Bioventus with a rating of Overweight and set a new price target of $12.00

      7/7/25 8:17:29 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Analyst with a new price target

      Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously

      12/17/24 7:32:13 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • BTIG Research initiated coverage on Apyx Medical

      BTIG Research initiated coverage of Apyx Medical with a rating of Neutral

      10/17/24 7:28:31 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    $BVS
    $XTNT
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

      BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. "We are pleased to welcome Lori to our Board, marking another high-quality independent member addition," said Stavros G. Vizirgianakis, Chairman of Xtant's Board of Directors. "Her deep operations, information technologies, and marketing expertise will be of significant va

      5/18/23 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APYX
    $BVS
    $XTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      11/8/24 9:13:26 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Apyx Medical Corporation

      SC 13G - Apyx Medical Corp (0000719135) (Subject)

      10/31/24 5:44:01 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apyx Medical Corporation

      SC 13G/A - Apyx Medical Corp (0000719135) (Subject)

      10/15/24 9:18:53 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care